Automatic Website Traffic RSS
Phosphodiesterase Inhibitors | AutoTraffic MSD leaps on FDA approval of PAH drug sotatercept
MSD’s sotatercept has become the first FDA-approved therapy for pulmonary arterial hypertension (PAH) that addresses the underlying mechanism behind the disease, rather than its symptoms.
read more Biologic Winrevair Wins FDA Approval for Treatment of PAH
The injectable activin signaling inhibitor is the first of this class to be approved by the FDA and is meant to be given every 3 weeks.
read more Phosphodiesterase Inhibitors in Clinical Urology
The introduction of inhibitors of the cyclic GMP phosphodiesterase (PDE) 5 into clinical urology is mainly the result of the characterization of the physiology of nonvascular and vascular penile ...
read more Paradigm Shift in COPD Treatment With New Wave Therapies
Experts express optimism regarding the COPD pipeline, indicating a strong probability of licensure for Dupixent and Ensifentrine.
read more PDE-4 Inhibitors for Psoriasis
Phosphodiesterase-4 (PDE-4) inhibitors are specialty drugs doctors prescribe to treat mild to severe plaque psoriasis. They work by lowering and managing inflammation, the underlying cause of ...
read more Sotatercept's FDA Approval a New Chapter for Pulmonary Arterial Hypertension
PAH is associated with high morbidity and mortality despite existing endothelin receptor antagonist and phosphodiesterase-5 inhibitor therapies. In the STELLAR trial, sotatercept improved exercise ...
read more Huge Study Confirms Viagra Cuts Alzheimer's Risk by Over 50%
An FDA-approved pharmaceutical used to treat erectile dysfunction could soon be recommended as a therapy for decreasing the risk of Alzheimer's disease.
read more Opsynvi, a Single-Tablet Combo Therapy for PAH, Gets FDA Approval
Opsynvi is a combination of macitentan, an endothelin receptor antagonist, and tadalafil, a phosphodiesterase 5 inhibitor. The Food and Drug Administration (FDA) has approved Opsynvi ® (macitentan and ...
read more Use of ED Drugs Associated With Lower Alzheimer Disease Risk
Among men with erectile dysfunction (ED), phosphodiesterase type 5 inhibitors (PDE5I) use vs nonuse is associated with reduced risk of developing Alzheimer disease (AD), according to study findings ...
read more New wave of potential therapies will bring shift in treatment paradigm for COPD
The current gap in the COPD market is the absence of biologics. However, Sanofi/Regeneron’s Dupixent, an interleukin-4 and interleukin-13 inhibitor, has the potential to address this gap, as positive ...
read more Subscribe to RSS Feed